心肝宝在拉米夫定乙肝抗病毒治疗中的疗效研究

Clinical Research of Xinganbao and Lamivudinevir on Treating Chronic Type B Hepatitis

[目的]观察心肝宝胶囊联合拉米夫定治疗慢性乙型肝炎及对停用拉米夫定后复发的影响。[方法]分为4组。单用组:单用拉米夫定治疗,拉米夫定100 mg,1次/d。联合组:拉米夫定12个月+心肝宝胶囊组;拉米夫定24个月+心肝宝胶囊组;拉米夫定100 mg,1次/d,心肝宝胶囊5粒/次,3次/d。[结果]单用拉米夫定停药6个月复发例数,24个月疗程组少于12个月疗程组,经统计学处理P>0.05,而联合治疗组拉米夫定24个月+心肝宝胶囊24个月,在停药6个月时复发例数与单用拉米夫定12个月复发例数比较,联合组少于单用组。经统计学处理χ2=5.6,P<0.05,有显著性差异。[结论]延长拉米夫定疗程,并加用心肝宝胶囊减少复发。

[Objective] To observe the clinical effect of Xinganbao capsule and lamivudinevir on treating chronic type B hepatitis and recudescent effect after stop using lamivudinevir [Methods] The sixty-two patients were randomly divided into five groups： Xiaoyan Tang in advance combined with chemotherapy （ten days, seven days, three days）; Xiaoyan Tang combined with chemotherapy; chemotherapy group. [Results] The recidivism rate of using lamivudinevir for twenty-four months was obviously lower than that of using lamivudinevir for twelve months（P〉0.05）. The recidivism rate of using lamivudinevir and Xinganbao capsule for twelve and twenty-four months was obviously lower than that of using lamivudinevir for twelve and twenty-four months（P〈0.05） [Conclusion] This method may decrrease recidivism rate of chronic type B heppatitis by delaying the curative course of lamivudinevir and combinating with Xinganbao capsule.